RxDoctor Payments Data

Tatyana Belimova

Nurse Practitioner · Harrisburg, PANPI 1114493186

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amgen at 34.4% of the total. Reporting peaked in 2021 at $2,806 and has fallen 80.8% since, to $537 in 2025. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,470in general payments, 2019–2025

Across 457 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • UCB, Inc.$807
  • AstraZeneca$767
  • GSK$566
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$10,27198%
  • Education$1992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,470 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$114,071
EnbrelEtanercept11$79,803
Orencia ClickjectAbatacept12$61,774
OtezlaApremilast12$56,269
MethotrexateMethotrexate Sodium126$4,219
Hydroxychloroquine Sulfate100$3,228
Pregabalin66$1,981
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$1,951
Leflunomide35$1,751
Gabapentin51$1,067
Acetaminophen-CodeineAcetaminophen With Codeine15$598
Duloxetine Hcl25$569
Tramadol Hcl100$505
Prednisone90$479
Tizanidine Hcl16$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$3,604$136,07223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →